Asset
BARICITINIB
Eli Lilly and Company Common Stock
Revenue
| Period | Revenue |
|---|---|
| Q4 2024 | $1.2B |
| Q3 2024 | $250.8M |
| Q2 2024 | $227.7M |
| Q1 2024 | $217.4M |
| Q4 2023 | $1.2B |
| Q3 2023 | $231.4M |
| Q2 2023 | $218.9M |
| Q1 2023 | $228.9M |
| Q4 2022 | $1.0B |
| Q3 2022 | $182.9M |
Revenue as reported by this company. A combination product's amount appears on each of its constituent assets, so those figures are not additive. A fourth quarter is the reported full year less nine months, since no filing states one.
Clinical trials (55)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT01859078 | phase1 | completed | 2013-05-01 | 2013-08-01 | Eli Lilly and Company | A Drug Drug Interaction (DDI) Study of Baricitinib (LY3009104) and Digoxin in Healthy Participants |
| NCT03428100 | phase3 | completed | 2018-05-15 | 2019-11-25 | Eli Lilly and Company | A Long-term Study of Baricitinib (LY3009104) With Topical Corticosteroids in Adults With Moderate to Severe Atopic Dermatitis That Are Not Controlled With Cyclosporine or for Those Who Cannot Take Oral Cyclosporine Because it is Not Medically Advisable |
| NCT01721044 | phase3 | completed | 2013-01-01 | 2014-06-01 | Eli Lilly and Company | A Moderate to Severe Rheumatoid Arthritis Study |
| NCT01870388 | phase1 | completed | 2013-06-01 | 2013-07-01 | Eli Lilly and Company | A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease |
| NCT01490632 | phase2 | completed | 2011-12-01 | 2012-12-01 | Eli Lilly and Company | A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis |
FDA applications (1)
| Application | Approved | Type | Applicant |
|---|---|---|---|
| NDA 207924 | 2018-05-31 | NDA | ELI LILLY AND CO |
Marketed products (3)
- OLUMIANT
- OLUMIANT
- OLUMIANT